Compound guide
A pathway-focused guide to molecular mechanisms, published evidence, and the limits of interpretation.
Overview
AOD-9604 is a modified peptide derived from the C-terminal region of human growth hormone and was developed to study lipid metabolism separately from full-length growth-hormone signaling.
Animal studies examined lipolysis, fat oxidation, and beta-adrenergic pathway involvement without conventional growth-hormone receptor activation.
Preclinical findings did not translate into a statistically significant primary weight-loss result in a larger human study reviewed by FDA. It should not be described as a proven fat-loss benefit.
Research model
These receptors, enzymes, and signaling networks define the primary laboratory questions associated with this research material.
AOD-9604 contains a modified sequence from the end of the growth-hormone molecule. Preclinical research suggests it does not engage the conventional growth-hormone receptor in the same way as full-length hormone.
Animal studies connect the fragment's activity with beta-adrenergic signaling in adipose tissue. This network can activate cyclic-AMP-dependent enzymes that release stored fatty acids from fat cells.
Preclinical work reported shifts toward fatty-acid oxidation and away from lipid accumulation. The exact direct target responsible for those observations remains uncertain.
Research interpretation
AOD-9604 contains a modified sequence from the end of the growth-hormone molecule.
Animal studies connect the fragment's activity with beta-adrenergic signaling in adipose tissue.
Preclinical work reported shifts toward fatty-acid oxidation and away from lipid accumulation.
Preclinical findings did not translate into a statistically significant primary weight-loss result in a larger human study reviewed by FDA. It should not be described as a proven fat-loss benefit.
Read the evidence
Continue exploring
More compounds organized within the metabolic signaling research area.
APX-3 is Apex’s catalog name for a single-peptide research compound that engages GLP-1, GIP, and glucagon signaling—an approach sometimes informally described as “GLP-3.”
Open compound guide ↗
5-Amino-1MQ is a small-molecule inhibitor used to study nicotinamide N-methyltransferase (NNMT), an enzyme involved in nicotinamide and methyl-donor metabolism.
Open compound guide ↗
APX-2 is the catalog name for tirzepatide (LY3298176), a peptide that engages two incretin receptors: GIPR and GLP-1R.
Open compound guide ↗One important note
The molecular model is based largely on animal and cell studies. In the larger human obesity study reviewed by FDA, AOD-9604 did not produce a statistically significant weight-loss advantage over placebo.
This guide summarizes molecular mechanisms, published evidence, and evidence limits in everyday language. It is educational information, not medical advice or instructions for personal use. Products offered on this site are intended exclusively for laboratory research and are not for human or veterinary use.
